Boston, Massachusetts 01124


Purpose:

The purpose of this research is to study the proteomic profile of individuals with ischemic brain injury. By comparing acute ischemic injury to other neurological diseases or systemic vascular injuries, researchers hope to further the understanding of ischemic brain injury.


Study summary:

The purpose of this study is to learn how the brain responds to vascular injuries such as stroke and/or to various medical or surgical treatments. The researchers will do this by examining naturally occurring proteins in the blood and urine using state-of-the-art proteomics techniques. Proteomics enables a "snapshot" of the body's chemistry at a specific time, either as part of normal daily function, or in response to a disease or treatment. Studying these snapshots will help scientists to better understand how people react to neurological disorders and treatments (such as thrombolysis or other interventions to save damaged brain). In the future, this knowledge may allow scientists to better tailor treatments, or to find the treatment that will be best for an individual person. The long-term goal is to use these snapshots to improve the ability to guide potentially life-saving therapy with a risky profile such as tissue plasminogen activator, or tPA, and finding new targets of intervention.


Criteria:

CASE: Inclusion Criteria: - Ischemic brain injury within 12 hours of symptom onset - Including primary ischemic brain injury from embolism or arterial occlusion or secondary due to increased ICP after trauma, subarachnoid hemorrhage. Exclusion Criteria: - Patients who are hemodynamically unstable for venipunctures - Anemic patients - Children - Pregnant women CONTROLS: Inclusion Criteria: - Healthy adults without any neurologic or systemic disease - Inpatient or outpatient adults with a chronic stroke (greater than 3 months) or chronic neurologic disease such as neurodegenerative disease, movement disorder, demyelinating disease - Inpatient or outpatient adults with systemic vascular disease. Exclusion Criteria: - Patients who are hemodynamically unstable for venipunctures - Anemic patients - Children - Pregnant women


NCT ID:

NCT00682331


Primary Contact:

Principal Investigator
MingMing Ning, MD
Massachusetts General Hospital

Dayse Sena, MD, PhD
Phone: 617-643-4637
Email: dsena@partners.org


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 01124
United States

MingMing Ning, MD
Phone: 617-724-0960
Email: MMNING@partners.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.